The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Schizophrenia, Paranoid

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Schizophrenia, Paranoid


Psychiatry related information on Schizophrenia, Paranoid


High impact information on Schizophrenia, Paranoid

  • Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain [8].
  • Although the amphetamine psychosis closely resembles paranoid schizophrenia and may be due to excess dopamine release, clinical, biochemical, and endocrine studies suggest that dopaminergic overactivity is not a necessary concomitant of schizophrenic illnesses [9].
  • In all of the brain areas studied, RELN and its mRNA were significantly reduced (approximately 50%) in patients with schizophrenia; this decrease was similar in patients affected by undifferentiated or paranoid schizophrenia [10].
  • METHOD: The Fused Rhymed Words Test was used to compare perceptual asymmetries in 16 patients with paranoid schizophrenia, 28 patients with undifferentiated schizophrenia, and 29 healthy comparison subjects [11].
  • In a placebo-controlled single-crossover study, seven patients with treatment-resistant chronic paranoid schizophrenia who received methadone plus neuroleptic showed significant improvement [12].

Chemical compound and disease context of Schizophrenia, Paranoid


Biological context of Schizophrenia, Paranoid


Anatomical context of Schizophrenia, Paranoid


Gene context of Schizophrenia, Paranoid


Analytical, diagnostic and therapeutic context of Schizophrenia, Paranoid


  1. Risperidone for the treatment of delusional disorder due to HIV disease. Maha, A., Goetz, K. The Journal of neuropsychiatry and clinical neurosciences. (1998) [Pubmed]
  2. Ulcerative colitis in association with chronic paranoid schizophrenia: a review of steroid-induced psychiatric disorders. Alcena, V., Alexopoulos, G.S. J. Clin. Gastroenterol. (1985) [Pubmed]
  3. Serum testosterone differences between patients with schizophrenia and those with affective disorder. Mason, J.W., Giller, E.L., Kosten, T.R. Biol. Psychiatry (1988) [Pubmed]
  4. Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients. Hong, C.J., Chiu, H.J., Chang, Y.S., Sim, C.B. Biol. Psychiatry (1998) [Pubmed]
  5. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Jacobsen, F.M. The Journal of clinical psychiatry. (1995) [Pubmed]
  6. Effects of chronic d-amphetamine on social behavior of the rat: implications for an animal model of paranoid schizophrenia. Gambill, J.D., Kornetsky, C. Psychopharmacology (Berl.) (1976) [Pubmed]
  7. Effects of pimozide on the psychopathology of delusional disorder. Silva, H., Jerez, S., Ramirez, A., Renteria, P., Aravena, N., Salazar, D., Labarca, R. Prog. Neuropsychopharmacol. Biol. Psychiatry (1998) [Pubmed]
  8. Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain. Farley, I.J., Price, K.S., McCullough, E., Deck, J.H., Hordynski, W., Hornykiewicz, O. Science (1978) [Pubmed]
  9. Dopamine and schizophrenia. Crow, T.J., Johnstone, E.C., Deakin, J.F., Longden, A. Lancet (1976) [Pubmed]
  10. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Impagnatiello, F., Guidotti, A.R., Pesold, C., Dwivedi, Y., Caruncho, H., Pisu, M.G., Uzunov, D.P., Smalheiser, N.R., Davis, J.M., Pandey, G.N., Pappas, G.D., Tueting, P., Sharma, R.P., Costa, E. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  11. Perceptual asymmetries in schizophrenia: subtype differences in left hemisphere dominance for dichotic fused words. Friedman, M.S., Bruder, G.E., Nestor, P.G., Stuart, B.K., Amador, X.F., Gorman, J.M. The American journal of psychiatry. (2001) [Pubmed]
  12. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Brizer, D.A., Hartman, N., Sweeney, J., Millman, R.B. The American journal of psychiatry. (1985) [Pubmed]
  13. Is loxapine more effective than chlorpromazine in paranoid schizophrenia? Rifkin, A., Rieder, E., Sarantakos, S., Saraf, K., Kane, J. The American journal of psychiatry. (1984) [Pubmed]
  14. Comments on "Amphetamine models of paranoid schizophrenia": a precautionary note. Rebec, G.V., Bashore, T.R. Psychological bulletin. (1982) [Pubmed]
  15. Paranoid schizophrenia and platelet MAO activity. Baron, M., Perlman, R., Levitt, M. The American journal of psychiatry. (1980) [Pubmed]
  16. Cocaine-induced delirium versus delusional disorder. Pearlson, G.D., Fischman, M.W., Foltin, R.W., Cornell, E., Pedroso, J.J. Biol. Psychiatry (1989) [Pubmed]
  17. Delusional disorder: molecular genetic evidence for dopamine psychosis. Morimoto, K., Miyatake, R., Nakamura, M., Watanabe, T., Hirao, T., Suwaki, H. Neuropsychopharmacology (2002) [Pubmed]
  18. The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Pierce, R.C., Bari, A.A. Reviews in the neurosciences. (2001) [Pubmed]
  19. Expression and characterization of a dopamine D4R variant associated with delusional disorder. Zenner, M.T., Nobile, M., Henningsen, R., Smeraldi, E., Civelli, O., Hartman, D.S., Catalano, M. FEBS Lett. (1998) [Pubmed]
  20. No association between polymorphisms in the DDC gene and paranoid schizophrenia in a northern Chinese population. Zhang, B., Jia, Y., Yuan, Y., Yu, X., Xu, Q., Shen, Y., Shen, Y. Psychiatr. Genet. (2004) [Pubmed]
  21. Subtypes of schizophrenia and ABO blood types. Rinieris, P., Stefanis, C., Lykouras, E., Varsou, E. Neuropsychobiology (1982) [Pubmed]
  22. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. Nechifor, M., Vaideanu, C., Palamaru, I., Borza, C., Mindreci, I. Journal of the American College of Nutrition. (2004) [Pubmed]
  23. Effects of thioridazine and fluphenazine on the pituitary, thyroid and adrenal functions in patients with paranoid schizophrenia. Horodnicki, J.M., Czekalski, S., Jarema, M. Psychiatr. Pol. (1984) [Pubmed]
  24. An association study between polymorphisms in three genes of 14-3-3 (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) family and paranoid schizophrenia in northern Chinese population. Jia, Y., Yu, X., Zhang, B., Yuan, Y., Xu, Q., Shen, Y., Shen, Y. Eur. Psychiatry (2004) [Pubmed]
  25. Association study between schizophrenia and monoamine oxidase A and B DNA polymorphisms. Coron, B., Campion, D., Thibaut, F., Dollfus, S., Preterre, P., Langlois, S., Vasse, T., Moreau, V., Martin, C., Charbonnier, F., Laurent, C., Mallet, J., Petit, M., Frebourg, T. Psychiatry research. (1996) [Pubmed]
  26. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Walsh, P., Spelman, L., Sharifi, N., Thakore, J.H. Psychoneuroendocrinology (2005) [Pubmed]
  27. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study. Tuason, V.B., Escobar, J.I., Garvey, M., Schiele, B. The Journal of clinical psychiatry. (1984) [Pubmed]
  28. Clinical diagnostic considerations on cocaine abuse. Palermo, G.B., Palermo, M.T. Journal of psychoactive drugs. (1990) [Pubmed]
WikiGenes - Universities